Exploration of the efficacy of anti‐immunoglobulin E monoclonal antibodies in the treatment of allergic asthma

• Published in: Immunology 2023-05, Vol.169 (1), p.96-101
• Main Authors: Qian, Xue‐Jiao, Hu, Xiao‐Tian, Jiang, Ping
• Format: Article
• Language: English
• Subjects: allergic asthma; Allergic rhinitis; Anti-Asthmatic Agents - adverse effects; Anti-Asthmatic Agents - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Asthma; Asthma - diagnosis; Asthma - drug therapy; Atopic dermatitis; chronic urticaria; Corticoids; Corticosteroids; Dermatitis; dynamic lung function; Effectiveness; Humans; Immunoglobulin E; Immunoglobulins; Monoclonal antibodies; Nitric oxide; omalizumab; Omalizumab - therapeutic use; Patients; Quality of Life; Respiratory function; Rhinitis; Rhinoconjunctivitis; Subgroups; Treatment Outcome; Urticaria
• ISSN: 0019-2805; 1365-2567
• DOI: 10.1111/imm.13613

The present study aims to evaluate the efficacy of an anti‐immunoglobulin E monoclonal antibody (omalizumab) in the treatment of allergic asthma (AS). A total of 34 patients with moderate‐to‐severe bronchial asthma admitted to the Respiratory Department of Tianjin First Central Hospital between September 2019 and September 2021 were enrolled in this study. The patients were treated with omalizumab in addition to conventional inhaled corticosteroids + long‐acting β2 agonist treatment. The therapeutic effects before and after the addition of omalizumab were compared. The lung function indicators (ratio of the forced expiratory volume [FEV] in the first second to the forced vital capacity, FEV in the first second, forced expiratory flow [FEF] at 50% of vital capacity, FEF at 75% of vital capacity, and maximum mid‐expiratory flow), fractionated exhaled nitric oxide values, asthma control test scores, rhinoconjunctivitis quality of life questionnaire scores, and urticaria control test scores were significantly different after 4 months of the regular administration of omalizumab (p